Recent Articles from GlobeNewswire

LOS ANGELES, May 04, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

For Immediate ReleaseNews Release

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

AUSTIN, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Global demand for service robotics is accelerating as industries increasingly turn to automation to address labor shortages, rising costs and operational inefficiencies. According to the International Federation of Robotics, service robot adoption continues to expand worldwide, with hundreds of thousands of units deployed annually and strong growth expected across hospitality, logistics and healthcare sectors. Market forecasts reinforce this trajectory, projecting the global service robotics market to grow from roughly $31 billion in 2026 to more than $131 billion by 2034, reflecting sustained double-digit growth driven by AI and automation adoption. Nightfood Holdings Inc. (OTC: NGTF) (Profile), (dba as TechForce Robotics), is positioning itself at the center of this transformation by focusing on real-world deployment, scalable infrastructure and strategic partnerships that enable global expansion in the AI robotics space. The company is focused on becoming an innovative leader in the robotics segment, aligned with others in the space, including Microsoft Corporation (NASDAQ: MSFT), ABB Ltd. (OTC: ABBNY), Rockwell Automation Inc. (NYSE: ROK) and Richtech Robotics Inc. (NASDAQ: RR).

FORT MYERS, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that John Kiernan, the Company’s President and Chief Executive Officer, will present and host one-on-one meetings with investors at the LD Micro Invitational XVI Conference, taking place on May 17-19, 2026 in Los Angeles, CA.

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Satellogic, Inc. (NASDAQ: SATL), a vertically integrated geospatial company delivering high-resolution Earth Observation (EO) at unprecedented scale and economics, today announced the addition of three senior industry veterans to its global sales organization: Matt Clark, Brett Davis, and Jonathan Lee.

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.

BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (NASDAQ: NEWT) (“NewtekOne”) announced that its bank subsidiary, Newtek Bank, N.A. (“Newtek Bank”), now offers its commercial banking customers the capability to receive instant payments through the Federal Reserve’s FedNow® Service and The Clearing House’s RTP® network twenty-four hours a day, seven days a week, 365 days per year.

MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

LOS ANGELES, May 04, 2026 (GLOBE NEWSWIRE) -- Raven Capital (“Raven”), an alternative investment firm specializing in asset-based, non-sponsor private credit, today announced that its portfolio company, Outback Presents, has completed the sale of a minority stake in its comedy business to AEG Presents, a leading global sports and live entertainment company.

SciTec selected to support $3.2 billion Space-Based Interceptor program for Golden Dome

NewGen records strong balance sheet with total assets of US$32.7 million

Fiserv Small Business Index remands steady at 144; year-over-year sales grew +1.1%

CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress.

SCALE CPO solution is the industry’s first OCI MSA capable platform and built with GF’s proven silicon photonics technology

Following the Company's recently announced $260 million enterprise contract for a 2,304-GPU NVIDIA B300 deployment, CEO will join national broadcast outlets to discuss Axe Compute's neocloud AI infrastructure platform

HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).

BOCA RATON, FL, May 04, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a $200 million at-the-market equity program.

LOS ANGELES, May 04, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Lexitas CEO to join industry leaders for panel discussion on the impact of AI across litigation support services

Fort Wayne, IN, May 04, 2026 (GLOBE NEWSWIRE) -- Premier Truck Rental (PTR), a nationwide custom truck, trailer and equipment provider, is proud to announce the addition of multiple new products to its portfolio, further strengthening its ability to serve customers in the utilities and construction markets.

MONTREAL, May 04, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has issued a conditional notice of redemption (the “Notice of Redemption”) for all of its outstanding 7.50% Senior Notes due 2029, in an aggregate principal amount of US$750,000,000 (the “2029 Notes”). As set forth in the Notice of Redemption, the redemption date is May 19, 2026, and the redemption price for the 2029 Notes is 103.750% of the principal amount redeemed, plus accrued and unpaid interest. The redemption of the 2029 Notes is subject to and conditioned upon Bombardier completing a new offering of debt securities in the aggregate principal amount of not less than US$500,000,000 before the May 19, 2026 redemption date (the “New Notes”); however, Bombardier may delay or waive this condition in its sole and absolute discretion. This debt redemption will be paid using proceeds from a New Notes offering and cash from Bombardier’s balance sheet.

SAN JOSE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries, today announced it has entered into a multi-year license agreement with L’Oréal for access to Adeia’s comprehensive media intellectual property (IP) portfolio.

MONTREAL, May 04, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500,000,000 aggregate principal amount of new Senior Notes due 2035 (the “New Notes”).Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to fund the repayment and/or retirement of outstanding indebtedness, including the redemption of all of its outstanding 7.50% Senior Notes due 2029 (the “2029 Notes”, and such redemption, the “Conditional 2029 Notes Redemption”), and (ii) to pay accrued interest and related fees and expenses. As of the date hereof, there is US$750,000,000 aggregate principal amount outstanding of the 2029 Notes.Consummation of the offering of the New Notes and the Conditional 2029 Notes Redemption are subject to market and other conditions, and there can be no assurance that Bombardier will be able to successfully complete these transactions on the terms described above, or at all. The Conditional 2029 Notes Redemption is expected to be subject to certain conditions, including the completion of the offering of the New Notes.This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful.The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. The securities mentioned herein may be offered and sold in the United States only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the U.S. Securities Act and outside the United States in reliance on Regulation S under the U.S. Securities Act. The securities mentioned herein have not been and will not be qualified for distribution to the public under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. The securities will be offered and sold in Canada on a private placement basis only to “accredited investors” pursuant to certain prospectus exemptions.This announcement does not constitute an offer to sell or the solicitation of an offer to buy the New Notes or an offer to purchase or solicitation of an offer to sell the 2029 Notes. This announcement does not constitute a redemption notice in respect of any 2029 Notes. Any redemption of the 2029 Notes will be made pursuant to a notice of redemption under the indenture governing such notes. 

OWEN SOUND, Ontario, May 04, 2026 (GLOBE NEWSWIRE) -- Serefin Health, in partnership with Brightshores Health System and the Grey-Bruce Ontario Health Team (OHT), today announced the launch of MyCareSteps, a proof-of-concept program, to support care coordination for residents across Grey and Bruce counties and to inform future approaches to coordinated care delivery.

NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel’s management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company’s extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer. The discussion will follow the oral plenary presentation of these data by Mark G. Garzatto, M.D., Professor of Urology at Oregon Health & Science University and the Portland VA Medical Center, at the American Urological Association (AUA) 2026 Annual Meeting.

Accomplished Acquisition Team of U.S. Army, SOCOM and Former Anduril Executive to Accelerate U.S. Government Growth, Contract Wins and Prime Contractor Partnerships

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for STAT6 inhibitor REX-8756 and STAT1/3 inhibitors will be highlighted in two oral presentations at the Society for Investigative Dermatology (SID) Annual Meeting taking place May 13-16, 2026, in Chicago, IL. REX-8756 is an oral, potent and selective STAT6 inhibitor being evaluated in an ongoing blinded, placebo-controlled Phase 1 clinical study.

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in May.

Advances Nanox’s ongoing U.S. commercialization and deployment efforts

Establishes Pittsburgh headquarters to support U.S. market expansion and SOLO™ deployment

Hong Kong, May 04, 2026 (GLOBE NEWSWIRE) -- Mint Incorporation Limited (“Mint” or the “Company”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, announces that it is implementing a reverse stock split of all of the Company's issued and unissued shares, including the Class A ordinary shares with no par value (the "Class A Ordinary Shares") and Class B ordinary shares with no par value (the “Class B Ordinary Shares,” together with the Class A Ordinary Shares, the "Ordinary Shares"), at an exchange ratio of one (1) share for ten (10) shares (the “Reverse Stock Split”). The Reverse Stock Split was approved by the Company’s Board of Directors on March 31, 2026.

Oral presentation includes early readouts from preclinical testing of CAR-encoding episomal DNA delivered by targeted lipid nanoparticles

Vancouver, BC , May 04, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered healthcare technology company focused on empowering doctors and expanding access to high-quality care, is pleased to announce that it has filed its audited annual financial statements for the fiscal year and fourth quarter ended December 31, 2025. The Company’s financial statements and Management’s Discussion and Analysis (“MD&A”) are available under its profile on SEDAR+ at www.sedarplus.ca.

New recognition program and proprietary research highlight how solopreneurs are using AI to replace traditional team functions and build scalable, independent businesses

-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy ---- Weight category improvements observed in pediatric patients with acquired hypothalamic obesity treated with setmelanotide --

Ahold Delhaize USA Brands’ Nearly 2,000 stores Now Available on Uber Eats Marketplace for On-Demand Delivery

First Wave of a Multi-Year, Multi-Format Retail Digitalization

Six-month data from adult Cohort 4 show structural and functional improvements and a favorable safety profile; early safety data from pediatric Cohort 5 are consistent with adult cohorts

GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community, announced that it has entered into a Second Amendment to the Loan and Security Agreement with Hercules Capital, Inc. (NYSE: HTGC). The Second Amendment increases the maximum borrowing capacity under the existing facility from $100 million to $140 million.

Praxis executes complete, AI-powered workflows end-to-end, turning enterprise operations into a self-improving intelligence engine.

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six years

Peer-reviewed research by General Fusion and Savannah River National Laboratory supports the tritium supply advantages of General Fusion’s practical Magnetized Target Fusion technology

Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas

Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio

Brings Total Capital Raised Across Accord Dislocation Complex to $11.6 Billion Since Inception

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands.

Grapevine, TX, May 04, 2026 (GLOBE NEWSWIRE) -- This May the Fourth, popularly called Star Wars Day, Patriot Mobile is calling on Americans to “use the Force” for good – announcing its growth as a company is enabling an even greater commitment to supporting faith, family, and freedom-focused initiatives nationwide.

FREIBURG, Germany and ROSCREA, Ireland, May 04, 2026 (GLOBE NEWSWIRE) -- Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis.

America’s No. 1 family entertainment brand, named a Newsweek America’s Greatest Workplace for Entry Level 2026, targets 3,200 new Cast Members this summer

New solution expands RILA access with additional buffer options, helps streamline product selection and delivers greater control

MAPLE GROVE, Minn., May 04, 2026 (GLOBE NEWSWIRE) -- EarthDaily Analytics (EarthDaily) today announced the successful launch of six EarthDaily Constellation satellites aboard a SpaceX Falcon 9 rideshare mission, confirming initial contact with satellites EDC-02 through EDC-07. The milestone significantly advances the company’s goal of delivering daily, consistent measurement of planetary change at global scale.

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, including one late-breaking oral presentation, of new data from the Phase 3 ATTRibute-CM study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF), taking place in Barcelona, Spain on May 9-12, 2026.

HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Fervo Energy (“Fervo” or the “Company”) today announced the launch of the Company’s roadshow for its initial public offering (“IPO”) of 55,555,555 shares of its Class A common stock. The IPO price is expected to be between $21.00 to $24.00 per share. Additionally, Fervo expects to grant the underwriters a 30-day option to purchase up to an additional 8,333,333 shares of the Company’s Class A common stock. Fervo has applied to list its Class A common stock on the Nasdaq, subject to official notice of issuance, under the ticker symbol “FRVO.”

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.

This substantially de-leverages the balance sheet with minimal remaining liabilities

Shelton, CT, May 04, 2026 (GLOBE NEWSWIRE) --

Multi-Year Agreement Extends Rekor as the Engine Behind One of the Nation's Most Successful Uninsured Motorist Reduction Programs

BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings.

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced that the Company will release its financial and operating results for the first quarter of 2026 prior to the market open on Thursday, May 14, 2026, Eastern Time (“ET”). The Company will then host a conference call to review the results later that day, at 2:00 pm ET. Those wishing to join the call can do so using the telephone numbers listed below. The call will also be webcast and available on the Company’s website at www.discoverysilver.com.

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million

Owners Kiran Mantripragada and Uday Kiran Namballa Anchors Franchise; Active Discussions With Sri Lankan Marquees Dasun Shanaka and Eshan Malinga Ahead of July–August 2026 Tournament Window

BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH) plans to report first quarter 2026 results on Tuesday, May 12, 2026. Management will present results during a conference call at 8:30 a.m. Eastern time.

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”) and an affiliate have provided a first lien senior secured term loan and a preferred equity investment in Security Fire Systems (“SFS”), aggregating approximately $26 million, in collaboration with Blackford Capital.

Represents achievement of strategic milestone for Cibus’ anticipated first commercial offering in the South American market

PENSACOLA, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- Advanced Technology Recycling (ATR), a leading IT Asset Management and Electronics Refurbishment company, is pleased to announce that we are now offering wholesale electronics to the general public through our online auction site. 

Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth

RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the U.S. Food and Drug Administration (“FDA”) has approved the Company’s supplemental Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for ASCENIV™. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.

OAK CREEK, Wis., May 04, 2026 (GLOBE NEWSWIRE) -- The Oak Creek-Franklin Joint School District (OCF) has announced a new partnership with Edustaff, a leading provider of educational staffing services, to enhance the district’s ability to recruit, place, and retain high-quality substitute teachers, paraprofessionals, and support staff across its schools. The collaboration is designed to ensure continuity of instruction and student support throughout the academic year.

SAN JOSE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today announced that it will release results for the first quarter ended March 31, 2026 on Thursday, May 14, 2026, prior to the market open.  

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally.